AbbVie (ABBV) Gains from Investment Securities (2012 - 2026)

AbbVie has disclosed Gains from Investment Securities across 15 years of filings, most recently posting $266.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 800.0% year-over-year to $266.0 million; the TTM figure through Mar 2026 stood at $307.0 million (down 90.01% YoY), while the FY2025 annual figure was $3.0 million, down 99.92% from the prior year.
• Gains from Investment Securities rose to $266.0 million in Q1 2026, from -$4.1 billion in the prior quarter.
• Over the last five years, Gains from Investment Securities for ABBV reached as high as $4.5 billion in Q4 2023 and fell as low as -$4.1 billion in Q4 2025.
• The 5-year median for Gains from Investment Securities is $303.0 million (2024), against an average of $600.7 million.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 1087.79% — and 2025, when it soared 1301.0%.
• A 5-year view of Gains from Investment Securities shows it stood at $86.0 million in 2022, then surged by 5083.72% to $4.5 billion in 2023, then sank by 42.33% to $2.6 billion in 2024, then slumped by 258.42% to -$4.1 billion in 2025, then jumped by 106.53% to $266.0 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $266.0 million, -$4.1 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.